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Objective: Recent randomized controlled trials have shown that age significantly affects the outcome of carotid
revascularization procedures. This study used data from the Society for Vascular Surgery Vascular Registry (VR) to
report the influence of age on the comparative effectiveness of carotid endarterectomy (CEA) and carotid artery stenting
(CAS).
Methods: VR collects provider-reported data on patients using a Web-based database. Patients were stratified by age and
symptoms. The primary end point was the composite outcome of death, stroke, or myocardial infarction (MI) at 30 days.
Results: As of December 7, 2010, there were 1347 CEA and 861 CAS patients aged <65 years and 4169 CEA and 2536
CAS patients aged>65 years. CAS patients in both age groups were more likely to have a disease etiology of radiation or
restenosis, be symptomatic, and have more cardiac comorbidities. In patients aged <65 years, the primary end point
(5.23% CAS vs 3.56% CEA; P  .065) did not reach statistical significance. Subgroup analyses showed that CAS had a
higher combined death/stroke/MI rate (4.44% vs 2.10%; P< .031) in asymptomatic patients but there was no difference
in the symptomatic (6.00% vs 5.47%; P  .79) group. In patients aged >65 years, CEA had lower rates of death (0.91%
vs 1.97%; P < .01), stroke (2.52% vs 4.89%; P < .01), and composite death/stroke/MI (4.27% vs 7.14%; P < .01). CEA
in patients aged >65 years was associated with lower rates of the primary end point in symptomatic (5.27% vs 9.52%;
P < .01) and asymptomatic (3.31% vs 5.27%; P < .01) subgroups. After risk adjustment, CAS patients aged >65 years
were more likely to reach the primary end point.
Conclusions: Compared with CEA, CAS resulted in inferior 30-day outcomes in symptomatic and asymptomatic patients
aged>65 years. These findings do not support the widespread use of CAS in patients aged>65 years. ( J Vasc Surg 2012;
55:1313-21.)
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MStroke is the third leading cause of death and the
leading cause of serious long-term disability in the United
States.1,2 Several landmark randomized clinical trials since
the 1990s have demonstrated the benefits of carotid end-
arterectomy (CEA) compared with medical therapy in sub-
groups of patients with carotid artery occlusive disease.3-6
To date, many still consider CEA to be the “gold standard”
for carotid revascularization procedures.
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doi:10.1016/j.jvs.2011.11.128Since its introduction almost 2 decades ago, carotid
ngioplasty and stenting (CAS) has been touted as an
lternative in patients at high risk for surgery.7,8 However,
he efficacy of CAS compared with CEA remains un-
lear.9,10 Furthermore, increasing age has been shown to
ave a negative effect on the outcomes of CAS.10-14 The
otential benefit of CAS in patients of increasing age there-
ore remains unclear.
The Society for Vascular Surgery (SVS) Vascular Reg-
stry (VR) on carotid procedures was developed to collect
ong-term outcomes for patients treated with CEA and
AS.15 As the first societal registry to enroll CEA and CAS
atients, the SVS-VR is one of the largest published data-
ases of carotid revascularization procedures in the United
tates. This study used the SVS-VR to evaluate the age-
tratified comparative effectiveness of CEA and CAS. The
enter for Medicare and Medicaid Services (CMS) will
ikely revisit the National Coverage Decision (NCD) on
AS in the near future; therefore, we used 65 years as the
utoff because this is the age for Medicare eligibility.
ETHODS
SVS-VR data are reported by providers through Web-
ased electronic data capture. The measurement schedule
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May 20121314 Jim et alincludes baseline preoperative information, such as patient
demographics, medical history, carotid symptom status,
preprocedural diagnostic imaging, laboratory results, and
procedural information, including clinical utility, proce-
dural and predischarge complications, as well as follow-up
information such as postprocedural death, stroke, myocar-
dial infarction (MI), and other morbidity.
All data entered into the VR are fully compliant with
the Health Insurance Portability and Accountability Act
(HIPAA) regulations and are auditable. All data reports
and analyses performed included only deidentified and
aggregated data. Additional details regarding the SVS-VR
have been previously discussed.15 New England Research
Institutes Inc (NERI, Watertown, Mass) maintains the
online database. Funding for the administration and data-
base management of the VR has been provided by the SVS
(Chicago, Ill).
Outcomes. The primary outcome measure is a com-
posite of the incidence of death, stroke, or MI. Stroke is
defined as any nonconvulsive, focal neurologic deficit of
abrupt onset persisting 24 hours. The ischemic event
must correspond to a vascular territory. An MI is classified
as either a Q wave MI in which one of the following criteria
is required: (1) chest pain or other acute symptoms consis-
tent with myocardial ischemia and new pathologic Q waves
in two or more contiguous electrocardiogram (ECG) leads;
or (2) new pathologic Q waves in two or more contiguous
ECG leads and elevation of cardiac enzymes; or non-Q
wave MI, which is defined as a creatine kinase (CK) ratio
2 and CK-MB 1 in the absence of new, pathologic Q
waves. Analysis of the 30-day outcomes was based on only
those patients who had at least a 30-day follow-up visit
(16 days) or who experienced an end point (death,
stroke, or MI) 30 days of treatment.
Statistical methods. Tests of statistical significance
were conducted with 2 or Fisher exact tests for categoric
Fig. Age distribution and procedure for patients. CAvariables and analysis of variance for continuous variables. pescriptive statistics are listed as mean  standard devia-
ion for continuous variables and percentage (frequency)
or categoric variables. Subset analyses were performed
sing the two-tailed t-test for continuous variables and the
2 or Fisher exact test, as necessary, for discrete and cate-
oric data. Unadjusted and adjusted odds ratios (OR) were
sed to compare the primary outcomes across treatment
roups and are presented with 95% confidence intervals
CI). The ORs were adjusted for any significant baseline
actors using logistic regression model. Differences were
onsidered significant at P  .05. All statistical analyses
ere performed by NERI using SAS software (SAS Insti-
ute, Cary, NC).
ESULTS
For the purpose of this report, data collected in the VR
rom the beginning of electronic data entry on July 11,
005 to December 7, 2010 were analyzed. There were
913 patients with 30-day follow-up data, of which 2208
24.8%) were aged 65 and 6705 (75.2%) were aged 65
ears. For those aged 65 years, 1347 (61.0%) underwent
EA and 861 (39.0%) had CAS. In patients aged 65
ears, 4169 (62.2%) underwent CEA and 2536 (37.8%)
ad CAS. The age distribution of patients in this study can
e found in the Fig.
Patient characteristics can be found in Table I. In both
ge groups, patients undergoing CEA and CAS had similar
ex and race distribution. However, the CAS subgroups
ad more patients with radiation (8.2% vs 0.1% [65 years]
nd 3.8% vs 0.2% [65 years]) and restenosis (21.6% vs
.8% [65 years] and 24.5% vs 1.5% [65 years]) as the
tiology of carotid artery disease. In those treated with
AS, the rate of symptomatic patients was higher (50.3% vs
3.4% [65 years] and 43.9% vs 36.3% [65 years]). The
AS groups also had a higher prevalence of several medical
omorbidities. The use of antiplatelet agents was more
rotid artery stenting; CEA, carotid endarterectomy.revalent in CAS patients (95.9% vs 91.2% [65 years] and
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Volume 55, Number 5 Jim et al 131597.5% vs 89.3% [65 years]). The CAS groups also had a
higher number of patients with baseline ultrasound-
documented stenosis 80% (77.5% vs 71.1% [65
years] and 76.8% vs 68.7% [65 years]) or contralateral
stenosis 70% (30.9% vs 22.0% [65 years] and 27.2%
vs 18.7% [65 years]).
Patients aged<65 years. In patients aged65 years
(Table II), the difference in the primary outcome of
composite death/stroke/MI (3.56% CEA vs 5.23%
CAS; P  .0647) did not reach statistical significance.
There were also no statistically significant differences in
the individual end points of death, stroke, or MI. After
risk adjustment for significant baseline factors, including
etiology (atherosclerosis), presence of coronary artery
Table I. Baseline demographics, disease etiology, medical
Patients 65 ye
CEA CA
Variablea (n  1347) (n  8
Demographics
Age, years 58.3 (35-64) 57.7 (18-
Male sex 60.1 (809) 59.3 (511
White race 89.7 (1208) 88.7 (764
Etiology
Atherosclerosis 98.5 (1327) 65.2 (561
Dissection 0.2 (3) 2.4 (21)
Fibromuscular dysplasia 0.1 (2) 0.1 (1)
Radiation 0.1 (1) 8.2 (71)
Trauma 0.1 (1) 0.7 (6)
Restenosis 0.8 (11) 21.6 (186
Other 0.1 (2) 1.7 (15)
Carotid symptoms
Symptomatic 43.4 (585) 50.3 (433
Medical history
Coronary artery disease 41.5 (559) 51.6 (444
Myocardial infarction 16.1 (217) 19.9 (171
Valvular heart disease 4.8 (65) 3.9 (34)
Cardiac arrhythmia 6.6 (89) 7.8 (67)
Congestive heart failure 6.0 (81) 12.0 (103
Hypertension 80.9 (1090) 79.2 (682
Diabetes 31.9 (430) 36.4 (313
Transient ischemic attack 20.2 (272) 23.3 (201
Stroke 22.0 (297) 29.3 (252
COPD 16.9 (228) 20.1 (173
Chronic renal failure 3.0 (40) 2.7 (23)
Transient monocular blindness 6.8 (91) 10.3 (89)
Peripheral vascular disease 44.5 (600) 36.7 (316
Gastrointestinal ulcer/bleeding 1.8 (24) 2.6 (22)
Current or past smoker 73.4 (989) 69.2 (596
Cancer 6.2 (83) 18.0 (155
Coagulopathy 1.3 (18) 1.2 (10)
ASA grade 2 90.3 (1216) 91.6 (789
NYHA scale 3 95.5 (1287) 88.3 (760
Antiplatelet use 91.2 (1229) 95.9 (826
Carotid evaluation
Baseline ultrasound 80% 71.1 (887/1247) 77.5 (538
Contralateral stenosis 70% 22.0 (274/1243) 30.9 (212
ASA, American Society of Anesthesiologists; CAS, carotid artery stenting;
NYHA, New York Heart Association.
aContinuous variables are presented as mean (range); categoric variables as
bP value for age was found using t-test. All others found using the Fisher exdisease, recent MI, congestive heart failure, stroke, ste-
b
bable II. Thirty-day outcomes for patients aged 65
ears by procedurea
Age 65 years, % (n)
CAS CEA
0-day events (n  861) (n  1347) Pb
ortality 1.16 (10) 0.74 (10) .3594
troke 3.48 (30) 2.82 (38) .3797
I 0.93 (8) 0.30 (4) .0716
eath/stroke/MI 5.23 (45) 3.56 (48) .0647
AS,Carotid artery stenting;CEA, carotid endarterectomy;MI,myocardial
nfarction.
Outcomes were defined as occurring intraoperatively, before discharge, orhistory, and carotid evaluation
ars Patients 65 years
S CEA CAS
61) Pb (n  4169) (n  2536) Pb
28) .0130 75.1 (65-98) 75.4 (65-96) .0557
) .7401 58.3 (2429) 59.9 (1520) .1768
) .4825 93.6 (3901) 93.4 (2368) .7520
) .0001 98.0 (4086) 70.3 (1784) .0001
0.1 (4) 0.3 (7)
0.1 (3) 0.2 (4)
0.2 (7) 3.8 (96)
0.0 (1) 0.1 (2)
) 1.5 (61) 24.5 (621)
0.2 (7) 0.9 (22)
) .0016 36.3 (1513) 43.9 (1114) .0001
) .0001 50.3 (2097) 60.6 (1538) .0001
) .0239 16.7 (697) 23.8 (603) .0001
.3316 9.3 (386) 7.3 (184) .0043
.2936 14.9 (621) 16.6 (421) .0616
) .0001 8.5 (356) 14.6 (371) .0001
) .3248 85.0 (3542) 83.8 (2125) .2001
) .0316 31.4 (1311) 32.4 (821) .4291
) .0783 19.4 (807) 24.5 (621) .0001
) .0001 21.3 (890) 24.6 (625) .0017
) .0598 17.8 (742) 19.6 (497) .0656
.6814 3.6 (149) 4.1 (105) .2388
.0027 4.9 (204) 6.7 (171) .0014
) .0003 46.0 (1916) 37.8 (959) .0001
.2146 3.1 (131) 4.9 (124) .0003
) .0324 55.8 (2326) 57.4 (1456) .1944
) .0001 15.3 (636) 19.3 (490) .0001
.7202 1.4 (60) 1.1 (28) .2423
) .2797 90.9 (3789) 91.8 (2328) .1999
) .0001 95.0 (3959) 89.0 (2258) .0001
) .0001 89.3 (3723) 97.5 (2473) .0001
/694) .0023 68.7 (2688/3912) 76.8 (1708/2225) .0001
/686) .0001 18.7 (728/3895) 27.2 (600/2208) .0001
CEA, carotid endarterectomy; COPD, chronic obstructive pulmonary disease;etween discharge and 30 days. Rates are per-patient.
P values were based on the Fisher exact test.
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May 20121316 Jim et alnosis 80%, and use of antiplatelet agents, CEA was
associated with a lower risk of MI (OR, 0.259; 95% CI,
0.068-0.985; P  .0474; Table III). After risk adjust-
ment, there remained no statistically significant differ-
ences in the rates of death, stroke, or the combined
primary end point in patients aged 65 years. In the
symptomatic subgroup, there was no difference in the
primary end point (5.47% CEA vs 6.00% CAS; P 
.7848; Table IV). Although there was no difference in
individual end points in the asymptomatic subgroup, the
composite death/stroke/MI end point was lower for
CEA (2.10% vs 4.44%; P .0306). After risk adjustment,
no differences remained in outcomes between symptom-
Table III. Risk-adjusted odds ratios (OR) for patients 6
Unadjusted
Event OR 95% CI
Death 0.636 0.264-1.536
Stroke 0.804 0.494-1.308
MI 0.318 0.095-1.058
Death/stroke/MI 0.670 0.442-1.015
CAS, Carotid artery stenting; CEA, carotid endarterectomy; CI, confidence
aAdjusted ORs calculated after adjusting for atherosclerosis, presence of coro
ultrasound, and use of antiplatelets agents.
bP values were based on the 2 test.
Table IV. Thirty-day outcomes for symptomatic and asym
Symptomatic, % (n)
CEA CAS
30-day events (n  585) (n  443)
Death 0.68 (4) 0.92 (4)
Stroke 4.79 (28) 4.62 (20)
MI 0.17 (1) 0.69 (3)
Death/stroke/MI 5.47 (32) 6.00 (26)
CAS, Carotid artery stenting; CEA, carotid endarterectomy; MI, myocardia
aOutcomes were defined as occurring intraoperatively, predischarge, or betw
bP values were based on the Fisher exact test.
Table V. Risk-adjusted odds ratios (ORs) for symptomatic
Unadjusted
30-day events OR 95% CI
Death 0.738 0.184-2.969
Stroke 1.038 0.577-1.868
MI 0.245 0.025-2.368
Death/stroke/MI 0.906 0.532-1.544
CAS, Carotid artery stenting; CEA, carotid endarterectomy; CI, confidence
aAdjusted ORs calculated after adjusting for atherosclerosis, presence of coro
ultrasound imaging, and use of antiplatelet agents.
bP values were based on the 2 test.atic patients aged 65 years (Table V). The risk of MI Approached statistical significance (OR, 0.189; 95% CI,
.035-1.025; P  .0534) in asymptomatic patients, but
here was no difference in the risk for the primary end
oint (OR, 0.501; 95% CI, 0.208-1.208; P  .1236;
able VI).
Patients aged >65 years. Patients aged 65 years
Table VII) undergoing CEA had a lower incidence of
eath (0.91% vs 1.97%; P  .0003) and stroke (2.52% vs
.89%; P  .0001). There was no difference in the rate of
I (1.39% CEA vs 1.30% CAS; P  .8280). Overall, the
omposite death/stroke/MI rate (4.27% vs 7.14%; P 
0001) was significantly lower in patients undergoing CEA.
rsa
CEA (vs CAS)
Adjusted
Pb OR 95% CI Pb
.3147 0.911 0.256-3.242 .8852
.3798 0.681 0.379-1.225 .1996
.0617 0.259 0.068-0.985 .0474
.0591 0.664 0.398-1.110 .1185
val; MI, myocardial infarction.
rtery disease, recent MI, congestive heart failure, stroke, stenosis 80% on
atic patients 65 years by treatment arma
Asymptomatic, % (n)
CEA CAS
Pb (n  762) (n  428) Pb
.7290 0.79 (6) 1.40 (6) .3679
.9999 1.31 (10) 2.34 (10) .2394
.3177 0.39 (3) 1.17 (5) .1447
.7848 2.10 (16) 4.44 (19) .0306
ction.
ischarge and 30 days. Rates are per-patient.
ents aged 65 yearsa
CEA (vs CAS)
Adjusted
Pb OR 95% CI Pb
6692 2.389 0.275-20.759 .4297
9011 0.730 0.370-1.441 .3642
2245 0.309 0.026-3.686 .3530
7161 0.811 0.429-1.532 .5182
val; MI, myocardial infarction.
rtery disease, recent MI, congestive heart failure, stroke, stenosis 80% on5 yea
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nary aptom
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Volume 55, Number 5 Jim et al 1317rates of death (OR, 0.592; 95% CI, 0.356-0.985; P 
.0436), stroke (OR, 0.459; 95% CI, 0.335-0.628; P 
.001), and composite death/stroke/MI (OR, 0.593; 95%
CI, 0.459-0.765; P  .001) in patients aged 65 years
(Table VIII).
Subgroup analyses also demonstrated CEA was associ-
ated with lower rates of the primary end point in symptom-
atic (5.95% vs 9.52%; P .0007) and asymptomatic (3.31%
vs 5.27%; P .0032) patients (Table IX). After risk adjust-
ment, CEA continued to be associated with lower risks of
stroke in symptomatic (OR, 0.475; 95% CI, 0.313-0.720;
P .0005) and asymptomatic (OR, 0.474; 95% CI, 0.292-
0.767; P  .0024) patients (Tables X and XI). The risk of
composite death/stroke/MI was also lower in symptom-
atic (OR, 0.475; 95% CI, 0.313-0.720; P  .0005) and
asymptomatic (OR, 0.474; 95% CI, 0.292-0.767; P 
.0024) patients.
DISCUSSION
Since its introduction in the 1990s, CAS has offered an
alterative to CEA in the treatment of carotid artery stenosis.
In March 2005, CMS approved coverage for CAS in symp-
tomatic patients who were at high risk for CEA. Since that
time, the comparative effectiveness of CEA and CAS con-
tinues to be debated despite the publication of results from
two large randomized clinical trials.9,10 Furthermore, the
Table VI. Risk-adjusted odds ratios (ORs) for asymptoma
Unadjusted
30-day events OR 95% CI
Death 0.558 0.179-1.742
Stroke 0.556 0.229-1.346
MI 0.334 0.080-1.406
Death/stroke/MI 0.462 0.235-0.908
CAS, Carotid artery stenting; CEA, carotid endarterectomy; CI, confidence
aAdjusted ORs calculated after adjusting for atherosclerosis, presence of coro
ultrasound imaging, and use of antiplatelet agents.
bP values were based on the 2 test.
Table VII. Thirty-day outcomes for patients aged 65
years by procedurea
Age 65 years, % (n)
CAS CEA
30-day events (n  2536) (n  4169) Pb
Death 1.97 (50) 0.91 (38) .0003
Stroke 4.89 (124) 2.52 (105) .0001
MI 1.30 (33) 1.39 (58) .8280
Death/stroke/MI 7.14 (181) 4.27 (178) .0001
CAS,Carotid artery stenting;CEA, carotid endarterectomy;MI,myocardial
infarction.
aOutcomes were defined as occurring intraoperatively, predischarge, or
between discharge and 30 days. Rates are per-patient.
bP values were based on the Fisher exact test.influence of age on clinical outcomes remains unclear. hAlthough some small series have reported excellent
esults of CAS in octogenarians,16,17 most studies have
emonstrated that advanced age is an independent predic-
or of in-hospital death and stroke after CAS. In the lead-in
hase of the Carotid Revascularization Endarterectomy vs
tenting Trial (CREST), periprocedural events after CAS
ere significantly affected by patient age.11 The 30-day
eriprocedural stroke and death rate increased with age:
.7% for patients aged 60, 1.3% for those 60 to 69, 5.3%
or those aged 70 to 79, and 12.1% for those aged 80
ears. Stanziale et al12 reported that octogenarians under-
oing CAS had a higher rate of 30-day stroke, MI, or death
9.2% vs 3.4%) than nonoctogenarians.
In a study of 5297 patients from the Carotid ACCU-
INK/ACCUNET Post Approval Trial to Uncover Rare
vents (CAPTURE 2) trial, combined death/stroke
ates were significantly higher for octogenarians than for
onoctogenarians (4.5% vs 3.0%) as were stroke rates
3.8% vs 2.4%).13 CREST data comparing the effect of
ge on the outcomes of CAS vs CEA showed an interac-
ion between age and treatment efficacy, with a crossover
t an age of 70 years; CAS tended to show greater
fficacy at younger ages and CEA at older ages.10 In a
ooled analysis of three trials (Endarterectomy Versus
ngioplasty in Patients With Symptomatic Severe Ca-
otid Stenosis [EVA-3S], Stent-Supported Percutaneous
ngioplasty of the Carotid Artery versus Endarterec-
omy [SPACE], and International Carotid Stenting
tudy [ICSS]) of patients with symptomatic carotid ste-
osis who could undergo surgery at standard risk, age
as the only subgroup variable that significantly modi-
ed the treatment effect.14 In patients aged 70 years,
he 120-day stroke or death risk was 5.8% in CAS and
.7% in CEA; in patients aged 70 years, there was an
stimated twofold increased risk with CAS vs CEA
12.0% vs 5.9%).
To understand why CAS in elderly patients is often
ssociated with poorer outcomes, several factors need to be
onsidered. Analyses of complications of CAS have high-
ighted the significant contribution of embolization origi-
ating from sources proximal to the treated lesion.18,19
ecause neurologic events can occur in the contralateral
atients aged 65 yearsa
CEA (vs CAS)
Adjusted
Pb OR 95% CI Pb
.3152 0.445 0.090-2.192 .3194
.1932 0.695 0.206-2.339 .5567
.1349 0.189 0.035-1.025 .0534
.0250 0.501 0.208-1.208 .1236
val; MI, myocardial infarction.
rtery disease, recent MI, congestive heart failure, stroke, stenosis 80% ontic p
inter
nary aemisphere as well as before the internal carotid lesion is
v
a
s
c
C
f
i
c
u
u
t
w
een d
JOURNAL OF VASCULAR SURGERY
May 20121318 Jim et alcrossed, manipulation with wires, catheters, and sheaths
in tortuous or diseased access vessels can contribute to
the complications seen with CAS. Elderly patients are
more likely to have heavily calcified aortic arches than
younger patients20 and to have other unfavorable ana-
tomic characteristics (such as arch elongation, common
carotid or innominate stenosis, and tortuosity) that in-
crease the technical difficulty of performing CAS.21 In
addition to anatomic considerations, patients aged 70
years with significant carotid stenosis may have compro-
mised intracranial collaterals and thus have poor cerebral
reserve.22 Older patients may thus be more sensitive to
minor cerebral emboli, which may contribute to a higher
Table VIII. Risk-adjusted odds ratios (ORs) for patients a
Unadjusted
30-day events OR 95% CI
Death 0.457 0.299-0.699
Stroke 0.503 0.386-0.655
MI 1.070 0.696-1.645
Death/stroke/MI 0.580 0.469-0.718
CAS, Carotid artery stenting; CEA, carotid endarterectomy; CI, confidence
aAdjusted ORs calculated after adjusting for atherosclerosis, presence of coro
ultrasound imaging, and use of antiplatelet agents.
bP values were based on the 2 test.
Table IX. Thirty-day outcomes for symptomatic and asym
Symptomatic, % (n)
CEA CAS
30-day events (n  1513) (n  1114)
Death 1.26 (19) 2.42 (27)
Stroke 3.77 (57) 6.73 (75)
MI 1.72 (26) 1.62 (18)
Death/stroke/MI 5.95 (90) 9.52 (106)
CAS, Carotid artery stenting; CEA, carotid endarterectomy; MI, myocardia
aOutcomes were defined as occurring intraoperatively, predischarge, or betw
bP values were based on the Fisher exact test.
Table X. Risk-adjusted odds ratios (ORs) for symptomatic
Unadjusted
30-day events OR 95% CI
Death 0.512 0.283-0.926
Stroke 0.542 0.381-0.772
MI 1.065 0.581-1.952
Death/stroke/MI 0.601 0.449-0.806
CAS, Ccarotid artery stenting; CEA, carotid endarterectomy; MI, myocard
aAdjusted ORs calculated after adjusting for atherosclerosis, presence of coro
ultrasound imaging, and use of antiplatelet agents.
bP values were based on the 2 test.stroke risk during CAS. eAlthough the studies mentioned here have noted the
arying outcomes in octogenarians as well as in those older
nd younger than 70, the age of 65 years was used in this
tudy. With publication of CREST and ICSS, two large
linical trials of carotid revascularization, we concluded that
MS would likely revisit the NCD on CAS in the near
uture. As such, the patients in this study were subdivided
nto those who would and would not qualify for Medi-
are coverage by their age. Data from the SVS-VR were
sed to analyze 30-day outcomes for 8913 patients who
nderwent carotid revascularization procedures. In pa-
ients aged 65 years old, outcomes of CEA and CAS
ere comparable, with no statistically significant differ-
65 yearsa
CEA (vs CAS)
Adjusted
Pb OR 95% CI Pb
.0003 0.592 0.356-0.985 .0436
.0001 0.459 0.335-0.628 .0001
.7576 1.086 0.648-1.819 .7551
.0001 0.593 0.459-0.765 .0001
val; MI, myocardial infarction.
rtery disease, recent MI, congestive heart failure, stroke, stenosis 80% on
atic patients 65 years by treatment arma
Asymptomatic, % (n)
Pb CEA CAS
(n  2656) (n  1422) Pb
.0340 0.72 (19) 1.62 (23) .0087
.0008 1.81 (48) 3.45 (49) .0016
.8789 1.20 (32) 1.05 (15) .7591
.0007 3.31 (88) 5.27 (75) .0032
ction.
ischarge and 30 days. Rates are per-patient.
ients 65 yearsa
CEA (vs CAS)
Adjusted
Pb OR 95% CI Pb
.0267 0.660 0.320-1.363 .2619
.0007 0.475 0.313-0.720 .0005
.8395 0.992 0.485-2.031 .9829
.0007 0.585 0.413-0.830 .0026
rction.
rtery disease, recent MI, congestive heart failure, stroke, stenosis 80% onged


inter
nary aptom
l infarpat
ial infa
nary ances in the unadjusted rates of death, stroke, and MI.
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end point, patients aged65 years undergoing CEA had
a lower risk of MI (OR, 0.259; P  .0474) than those
undergoing CAS.
This finding differs from the results of CREST, in
which the incidence of periprocedural MI was lower in the
stenting group.10 In this study, the rates of MI in CEA
patients (0.30% in65 and 1.39% in65 years) were lower
than those reported in all patients from CREST (2.3%) but
were higher than the rate (0.4%) reported in the pooled
European trials.10,14 In evaluating patients aged65 years,
CEA was associated with lower rates of death (0.91% vs
1.97%; P  .0003), stroke (2.52% vs 4.89%; P  .0001),
and the primary composite end point of death/stroke/MI
(4.27% vs 7.14%; P  .0001). After risk adjustment, CEA
continued to be associated with lower risks of death (OR,
0.592; P  .0436), stroke (OR, 0.459; P  .0001), and
death/stroke/MI (OR, 0.593; P .0001). The outcomes
of CAS in patients aged 65 years remained inferior to
those with CEA when patients were divided into the symp-
tomatic and asymptomatic subgroups.
The results in this study may differ slightly from those
published in CREST because the data from the SVS-VR
represent real-world outcomes. The SVS-VR is available to
all clinical facilities and providers in the United States
wishing to participate. As such, although the VR suffers
from self-reporting bias, it includes a broad collection of
institutions and physicians, thus possibly presenting data
that coincide with results found in the real world.
In addition, CAS has a significant procedurally related
learning curve, and numerous studies have demonstrated
the importance of operator experience in the clinical suc-
cess of CAS.23-26 Implanting physicians in CREST were
certified only after a satisfactory evaluation of their experi-
ence, results, and participation in a lead-in phase of train-
ing.10 This type of credentialing and monitoring process
certainly does not exist in routine practice on a national
level. Studies of carotid revascularization have demon-
strated different results in actual practice compared with
those reported in clinical trials.
Outcome disparities have been shown in Medicare
patients undergoing CEA, who had a much higher periop-
Table XI. Risk-adjusted odds ratios (ORs) for asymptoma
CEA (vs CAS)
Unadjusted
30-day events OR 95% CI
Death 0.438 0.238-0.807
Stroke 0.516 0.345-0.772
MI 1.144 0.617-2.119
Death/stroke/MI 0.615 0.449-0.843
CAS, Carotid artery stenting; CEA, carotid endarterectomy; CI, confidence
aAdjusted ORs calculated after adjusting for atherosclerosis, presence of coro
ultrasound imaging, and use of antiplatelet agents.
bP values were based on the 2 test.erative mortality rate than that reported in trials, even omong institutions that participated in the randomized
tudies.27 A more recent study also showed that patients
ndergoing CAS who participated in company-sponsored
ostmarketing surveillance studies had less baseline neuro-
ogic disease and lower mortality rates compared with
AS patients who did not participate in the studies.28 As
uch, practice guidelines and policy changes may be more
ppropriately based on findings of comparative effective-
ess seen in real-world settings as opposed to efficacy
emonstrated in carefully controlled clinical trials.
Several limitations of this study warrant further discus-
ion. The main limitation is that data from registries such as
he SVS-VR are not designed to mimic clinical trials. Thus,
ot all clinical factors that result in treatment bias can be
eadily identified. Anatomic information (such as plaque
haracteristic, degree of vessel tortuosity, calcification)
nd other important factors (such as operator experi-
nce) were not available, and any confounding effects
hese factors may have on the study outcomes cannot be
dequately analyzed.
There are also limitations specific to secondary data
nalyses of databases such as the SVS-VR. We must again
ote that data are self-reported by treating physicians and
nstitutions. The potential effect of reporting bias within
he SVS-VR has been investigated and discussed.7 Finally,
s with all studies using registry data, the collected infor-
ation is retrospective. However, data from independent
nd verifiable registries still can provide valuable informa-
ion about clinical outcomes in the absence of randomized
vidence.
ONCLUSIONS
The results from this multicenter observational study
emonstrated that CAS was associated with higher rates of
ostoperative complications compared with CEA. Al-
hough CAS may be preferred over CEA in some situations
ecause of certain medical risk factors or anatomic consid-
rations, identification for this subset of patients was be-
ond the scope of this study.However, the current available
vidence simply does not support the widespread use of
AS. Our analysis of data from a registry on carotid revas-
ularization procedures found that patients aged65 years
atients 65 yearsa
Adjusted
Pb OR 95% CI Pb
.0081 0.546 0.265-1.124 .1005
.0013 0.474 0.292-0.767 .0024
.6692 1.379 0.629-3.020 .4224
.0025 0.649 0.443-0.953 .0273
vals, MI, myocardial infarction.
rtery disease, recent MI, congestive heart failure, stroke, stenosis 80% ontic p
inter
nary ald undergoing CAS had higher rates of death and stroke,
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May 20121320 Jim et aland combined death/stroke/MI, than those undergoing
CEA. The findings in this report do not support the wide-
spread use of CAS in patients aged 65 years old.
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Dr Joseph Hart (Charleston, SC). I congratulate the authors
on a great study and a very complete manuscript with an enormous
amount of data. Thank you. They looked at approximately 9000
carotid revascularization procedures and stratified them by age
from the Society for Vascular Surgery Vascular Registry. It appears
to be, again, a large, rigorously analyzed study with the stated
limitations that the authors have mentioned.
I am going to stick with two questions for now. Most of us
here are young or early-to- midcareer vascular surgeons or trainees.
If we are not going to offer carotid stents to people over 65, is there
anyone we should offer them to? As someone who is pretty
interested in carotid stenting, I am careful to try to avoid offering
them to people who are young for durability concerns, although
there is certainly a lot of literature that the young do well.
Secondly, you acknowledged in your discussion, and more so
in the manuscript, the importance of arch anatomy in older pa-
tients. Is it possible that if you had these patients’ arch anatomy
better stratified and looked at the patients split out that way that
you might see that that was as or more important a variable?
Thanks to the Society and the authors for the opportunity to
review this.
Dr Jeffrey Jim. Thank you for the questions. To address the
first question, the long-term results will determine who we should
offer it to. If you look at the Carotid Revascularization Endarter-
ectomy vs Stenting Trial (CREST), it really shows the benefit of
stenting compared to endarterectomy in patients who are younger.
However, as you noted, there are durability concerns, and we
simply do not have high-quality data that extend out to 5 years, 10
years, or even longer for stenting.
In terms of who to offer it to, I think there’s certainly still a
subgroup of patients that definitely benefit from stenting. While
we cannot tease them out in this type of registry analysis, these
patients are the ones where stenting was first introduced for:
restenosis, radiation damage, neck dissection, and other high-risk
anatomic factors.
Your second question: while we have a pretty good amount of
anatomic information in this registry, we do not have information
on arch anatomy. I briefly discussed this topic in the manuscript,
and there are good studies that have shown the early phases of the
stenting procedure can cause perioperative strokes even before
crossing the internal carotid lesion. In Europe, there is a lot of
experience with direct cervical puncture and open cervical carotid
exposure, and that can eliminate a significant amount of perioper-
ative strokes. I am certain that if we were able to tease out some of
the arch information, the stroke rate in carotid artery stenting in
the elderly patients will come down.Dr Hart. I think that is an interesting approach for that
problem. I personally am not a huge fan of the direct cervical
a
rpproach because it is kind of the worst of both worlds. A lot of
imes they are asleep and the devices aren’t made to be used in that
hort of a distance, by and large. But I think that is one approach,
nd the other would just be to image anyone you can to look at
heir arch.
Dr Ralph Pfeiffer (Mobile, Ala). I guess I am one of the older
urgeons. I have been doing this for about 30 years and do both
tenting and endarterectomy. My question, though, is will the
enter for Medicare and Medicaid Services (CMS) use this infor-
ation to prevent the approval of paying for Medicare patients
aving carotid stenting, asymptomatic patients, other than in
rials?
Dr Jim. Our main objective was to investigate the impact of
ge in a real-world setting. Like I said in answering the first
uestion, there are definitely patients who are going to benefit
rom stenting. The question is to identify this subgroup. The data
rom CREST and with this study simply do not support uniformly
ffering stenting to elderly patients. I think we need to figure out
ho can benefit so we can offer them carotid stenting.
Dr Pfeiffer. Don’t you think that CMS will use this data,
hough, this raw data from the general population as opposed to
pecific studies in deciding whether to approve paying forMedicare
atients over age 65 to have carotid stenting when they have
symptomatic disease?
Dr Jim. I don’t really know what CMS is going to do.
bviously, when the national coverage decision is revisited, the
opic will be hotly debated. I think the question always comes
own to what the data show. Randomized clinical trials will remain
he gold standard for comparative studies in looking at efficacy.
owever, we also feel that the comparative effectiveness in real-
orld outcomes may be even more important.
Dr Rajeev Dayal (New York, NY). Wasn’t the carotid artery
tenting group composed of sicker patients with greater amounts
f coronary artery disease, and would that explain the rate of
yocardial infarction (MI) in the CAS group? How were the MIs
djudicated? Were there just enzyme leaks or was there true
ymptomatology with electrocardiography changes? Lastly, did
ou do a propensity analysis to identify patients within both
reatment groups that had equivalent rates of comorbidities and
ompare those two groups to see what their combined death,
troke, and MI rates were?
Dr Jim. To answer your first question, definitions were estab-
ished for the clinical end points. An MI was determined based on
linical symptoms, electrocardiography changes, and enzyme lev-
ls. The stenting group definitely had a higher prevalence of
oronary artery disease and we did our best to take that into
ccount when we did the risk-adjusted outcomes. We performed
isk-adjustment but did not do a propensity analysis.
